Late divergence of survival curves in cancer immunotherapy trials: interpretation and implications
- First Online:
- Cite this article as:
- Thorén, F.B., Anderson, H. & Strannegård, Ö. Cancer Immunol Immunother (2013) 62: 1547. doi:10.1007/s00262-013-1458-y
- 250 Downloads
Late divergence of survival curves of treated patients and controls is commonly seen in successful cancer immunotherapy trials. Although late survival curve divergence may be caused by a delayed action of therapy, it may also be related to early effects of the treatment. We suggest that late survival divergence most often reflects a specific benefit of therapy for patients who suffer from a comparatively slow progression of disease. The occurrence of delayed survival curve divergence has important implications for the statistical analysis of immunotherapy trials. Thus, it leads to non-proportional hazard ratios that make commonly used statistical tests, e.g., the logrank test, suboptimal. It is therefore suggested that the statistical analysis of immunotherapy trials primarily should be based on a test that compares the survival curves at or after a prespecified, fixed, late time point.